DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 40.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,791 shares of the medical device company’s stock after selling 6,096 shares during the quarter. Advisors Asset Management Inc.’s holdings in DexCom were worth $589,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC increased its stake in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after acquiring an additional 11,075 shares during the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom in the third quarter valued at about $683,000. National Pension Service grew its stake in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares in the last quarter. Intact Investment Management Inc. acquired a new stake in shares of DexCom in the third quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC grew its stake in shares of DexCom by 4.2% in the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after buying an additional 10,892 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.2 %

Shares of NASDAQ DXCM opened at $78.10 on Thursday. The company has a market cap of $30.51 billion, a price-to-earnings ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock’s 50 day simple moving average is $71.11 and its 200 day simple moving average is $88.51.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DXCM. Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Robert W. Baird increased their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Leerink Partners lowered their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.